A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP.

摘要: It is known that there a very high incidence of hepatocellular carcinoma (HCC) among patients with type C chronic hepatitis and cirrhosis, α -fetoprotein (AFP) has been widely used as diagnostic marker for HCC. However, are some showing continuous AFP values but no evidence HCC, studies have defined such high-risk group In vitro study shown interferon (IFN) inhibits cell proliferation enhances apoptosis well specific cytotoxic T lymphocytes against resulting in direct anticancer actions. this study, we investigated the effect IFN on changes patients. Of 40 whom imaging confirmed absence 24 showed pretreatment (high group: level > 10 ng/dl; mean ± SD, 46.3 41.5 ng/dl) 16 low (low ≤ 5.3 2.2 ng/dl). Pretreatment clinical parameters were statistically evaluated relation to value. group, platelet count, albumin level, prothrombin (%) significantly lower (P = 0.047, P 0.0002, 0.044, respectively), suggesting value increases advancing liver disease. Subsequently 27 administered (IFN group), remaining 13 Stronger Neo-minophagen (SNMC), glycyrrhizin preparation (SNMC control receiving liver-protective therapy. Alanine aminotransferase was reduced both SNMC (mean, 132.56 60.07 mg/ml [P < 0001] 147.85 56.23 0.0240], respectively). 30.03 12.65 ng/ml; 0.0034), significant change 29.70 39.17 ng/ml). useful diagnosing HCC; however, show persistently these described found therapy not universally baseline. Since predictor therapeutic strategies C, e.g., long-term low-dose treatment, may reduce hepatocarcinogenesis.